Month: August 2021

SPRINT BIOSCIENCE LICENSES THE CANCER DRUG PROGRAM VPS34 TO DECIPHERA PHARMACEUTICALS

Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals. The license agreement covers exclusive global rights to the program. The agreement has a total potential value of up to USD 277 million, plus additional tiered percentage royalties ranging from the mid-single-digits […]
Read More